China-based Changchun BCHT Biotechnology Co., Ltd (SHA: 688276) has announced plans to invest RMB 805 million (USD 110 million) in the production of 10 million annual doses of its influenza virus split vaccine (BK-01 adjuvant). This substantial investment includes RMB 659 million for industrialization and RMB 146 million for operational working capital, reflecting the company’s commitment to enhancing vaccine production capabilities over a 7-year program.
Investment Breakdown and Program Timeline
The comprehensive program will span pre-clinical studies, clinical trials, and industrialization phases, ensuring a robust development pipeline for the BK-01 adjuvant vaccine. This strategic investment aims to solidify Changchun BCHT Biotechnology’s position in the influenza vaccine market, addressing the ongoing need for effective immunization solutions.
BK-01 Adjuvant: Targeting Broad Immune Response
The BK-01 adjuvant is designed to stimulate immune responses in populations aged 6 months and above, with a particular focus on improving protection among the elderly. The vaccine is expected to produce high antibody levels in individuals aged 60 and above, achieving significant protective effects against influenza. This targeted approach underscores the company’s dedication to public health, especially in vulnerable populations.-Fineline Info & Tech
